{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:17:53Z","timestamp":1792642673253,"version":"4.5.0"},"reference-count":161,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chronic hepatitis B remains difficult to cure because viral persistence is maintained within hepatocytes through covalently closed circular DNA and integrated viral sequences that continue to drive antigen production even when viral replication is effectively suppressed. Although current antiviral therapies improve clinical outcomes and slow disease progression, they rarely achieve a durable functional cure, defined as sustained loss of hepatitis B surface antigen (HBsAg), with or without anti-HBs seroconversion. This limitation has shifted attention toward therapeutic strategies that depend on precise and reliable drug delivery to the liver. Several recent reviews have focused on antiviral mechanisms or immune modulation. However, the specific contribution of drug delivery to therapeutic success has not been systematically addressed. This review examines hepatocyte-targeted drug delivery as a central determinant of success for emerging hepatitis B therapies. Rather than cataloging individual therapeutic agents, this review adopts a delivery-centered framework that links viral persistence biology with translational feasibility across therapeutic classes. Recent advances in ligand-mediated hepatocyte targeting have demonstrated consistent liver specificity and clinical feasibility, enabling meaningful reductions in viral transcripts and antigens. At the same time, we discuss why more complex delivery platforms continue to face challenges related to intracellular access, immunogenicity, scalability, and safety during repeated dosing, particularly for strategies intended to act within the nucleus. Translational and clinical considerations, including differences between experimental models and human infection, manufacturing and regulatory constraints, and the demands of long-term treatment, are also addressed. Overall, this review supports a pragmatic path toward functional cure based on rational combination therapies, coordinated delivery strategies, and patient-tailored approaches, with delivery science serving as the critical link between biological insight and durable clinical benefit.<\/jats:p>","DOI":"10.3390\/pharmaceutics18020212","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:41:02Z","timestamp":1770630062000},"page":"212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatocyte-Targeted Drug Delivery Strategies for Chronic Hepatitis B: Overcoming Delivery Barriers Toward Functional Cure"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-9532","authenticated-orcid":false,"given":"Ayman","family":"Elbehiry","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-0633","authenticated-orcid":false,"given":"Musaad","family":"Aldubaib","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnosis, College of Veterinary Medicine, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2025). Hepatitis B, WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b?."},{"key":"ref_2","unstructured":"World Health Organization (WHO) (2024). WHO Sounds Alarm on Viral Hepatitis Infections Claiming 3500 Lives Each Day, WHO. Available online: https:\/\/www.who.int\/news\/item\/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day?."},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2024). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries, WHO. Available online: https:\/\/www.globalhep.org\/sites\/default\/files\/content\/resources\/files\/2024-04\/2024%20Global%20Hepatitis%20Report%20-%20WHO.pdf?."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_5","unstructured":"American Association for the Study of Liver Diseases (AASLD) (2025). AASLD Announces New Practice Guideline on Treatment of Chronic Hepatitis B, AASLD. Available online: https:\/\/www.aasld.org\/aasld-announces-new-practice-guideline-treatment-chronic-hepatitis-b?."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL) (2025). EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 83, 502\u2013583.","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","unstructured":"Gane, E.J., Yuen, M., Alina, J., Kha, L., Christopher, W., Christian, S., Agarwal, K., Qingling, Z., Lawrence, B., and Sushmita, C. (2021, January 12\u201315). Safety, Pharmacokinetics, and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B. Proceedings of the Liver Meeting\u00ae (AASLD), Virtual. Abstract 843."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor myrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMoa2213429","article-title":"Bulevirtide for Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2023.01.017","article-title":"Eliminating cccDNA to cure hepatitis B virus infection","volume":"78","author":"Zoulim","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Allweiss, L., and Dandri, M. (2017). The role of cccDNA in HBV maintenance. Viruses, 9.","DOI":"10.3390\/v9060156"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wei, L., and Ploss, A. (2021). Mechanism of hepatitis B virus cccDNA formation. Viruses, 13.","DOI":"10.3390\/v13081463"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Moreno, A., and Ploss, A. (2024). Mechanisms of hepatitis B virus cccDNA and minichromosome formation and HBV gene transcription. Viruses, 16.","DOI":"10.3390\/v16040609"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0037-1606212","article-title":"Challenges to a cure for HBV infection","volume":"37","author":"Testoni","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.coviro.2016.06.003","article-title":"HBV cure: Why, how, when?","volume":"18","author":"Levrero","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: A systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2013FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tu, T., Budzinska, M.A., Shackel, N.A., and Urban, S. (2017). HBV DNA integration: Molecular mechanisms and clinical implications. Viruses, 9.","DOI":"10.3390\/v9040075"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bousali, M., Papatheodoridis, G., Paraskevis, D., and Karamitros, T. (2021). Hepatitis B virus DNA integration, chronic infections and hepatocellular carcinoma. Microorganisms, 9.","DOI":"10.3390\/microorganisms9081787"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/jvh.13356","article-title":"Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA","volume":"27","author":"Ringlander","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos (t) ide analogue-treated patients","volume":"68","author":"Yip","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","article-title":"Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination","volume":"30","author":"Dembek","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Montali, I., Vecchi, A., Rossi, M., Tiezzi, C., Penna, A., Reverberi, V., Laccabue, D., Missale, G., Boni, C., and Fisicaro, P. (2022). Antigen load and T cell function: A challenging interaction in HBV infection. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061224"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/s-0037-1617455","article-title":"Liver sinusoidal endothelial cell: An update","volume":"37","author":"DeLeve","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101436","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Bremmell","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-5926-1-1","article-title":"Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review","volume":"1","author":"Braet","year":"2002","journal-title":"Comp. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cogger, V.C., Hunt, N.J., and Le Couteur, D.G. (2020). Fenestrations in the liver sinusoidal endothelial cell. Liver Biol. Pathobiol., 435\u2013443.","DOI":"10.1002\/9781119436812.ch35"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1021\/acsnano.7b06995","article-title":"Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake","volume":"12","author":"Campbell","year":"2018","journal-title":"ACS Nano"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E10871","DOI":"10.1073\/pnas.1713390114","article-title":"Effect of removing Kupffer cells on nanoparticle tumor delivery","volume":"114","author":"Tavares","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","article-title":"Elimination pathways of nanoparticles","volume":"13","author":"Poon","year":"2019","journal-title":"ACS Nano"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17425247.2024.2375400","article-title":"Understanding nanoparticle-liver interactions in nanomedicine","volume":"21","author":"He","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cunningham, R.P., and Porat-Shliom, N. (2021). Liver zonation\u2013revisiting old questions with new technologies. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.732929"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.32408","article-title":"Liver zonation, revisited","volume":"76","author":"Paris","year":"2022","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: The great endosomal escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: A bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/s41467-025-61965-x","article-title":"Dual-targeted siRubicon delivery strategy triggers hepatocellular lipophagy for mitigating liver steatosis","volume":"16","author":"Lan","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1039\/D4MD00652F","article-title":"Hepatocyte targeting via the asialoglycoprotein receptor","volume":"16","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"ChemBioChem"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, H., Hong, L., Wang, H., Li, B., Zhang, M., Li, J., Yang, L., and Liu, F. (2023). Inclisiran: A new generation of lipid-lowering siRNA therapeutic. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1260921"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","article-title":"Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression","volume":"26","author":"Willoughby","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18789","DOI":"10.1039\/D4SC05606J","article-title":"Strategic design of GalNAc-helical peptide ligands for efficient liver targeting","volume":"15","author":"Ito","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"Rna"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zhang, L., Liang, Y., Liang, G., Tian, Z., Zhang, Y., Liu, Z., and Ji, X. (2022). The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1090237"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bhandari, S., Larsen, A.K., McCourt, P., Smedsr\u00f8d, B., and S\u00f8rensen, K.K. (2021). The scavenger function of liver sinusoidal endothelial cells in health and disease. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.757469"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2212206","DOI":"10.1002\/adma.202212206","article-title":"Restoration of sinusoid fenestrae followed by targeted nanoassembly delivery of an anti-fibrotic agent improves treatment efficacy in liver fibrosis","volume":"35","author":"Li","year":"2023","journal-title":"Adv. Mater."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"19767","DOI":"10.1039\/D5NR01664A","article-title":"Data-driven optimization of nanoparticle size using the prediction reliability enhancing parameter (PREP)","volume":"17","author":"Tayebi","year":"2025","journal-title":"Nanoscale"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103046","DOI":"10.1016\/j.copbio.2023.103046","article-title":"Impact of protein coronas on nanoparticle interactions with tissues and targeted delivery","volume":"85","author":"Chou","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9664","DOI":"10.1038\/s41598-020-66572-y","article-title":"Controlling evolution of protein corona: A prosperous approach to improve chitosan-based nanoparticle biodistribution and half-life","volume":"10","author":"Tekie","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1039\/D5PM00079C","article-title":"A new strategy for the extrahepatic delivery of lipid-based nanomedicines: A protein corona-mediated selective targeting system based on an ionizable cationic lipid library","volume":"2","author":"Younis","year":"2025","journal-title":"RSC Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Swetha, K., Kotla, N.G., Tunki, L., Jayaraj, A., Bhargava, S.K., Hu, H., Bonam, S.R., and Kurapati, R. (2023). Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. Vaccines, 11.","DOI":"10.20944\/preprints202302.0142.v1"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.impact.2016.09.005","article-title":"Protein corona influences liver accumulation and hepatotoxicity of gold nanorods","volume":"3","author":"Cai","year":"2016","journal-title":"NanoImpact"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"0148","DOI":"10.34133\/research.0148","article-title":"Advanced strategies for overcoming endosomal\/lysosomal barrier in nanodrug delivery","volume":"6","author":"Qiu","year":"2023","journal-title":"Research"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102506","DOI":"10.1016\/j.cbpa.2024.102506","article-title":"Strategies and mechanisms for endosomal escape of therapeutic nucleic acids","volume":"81","author":"Grau","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2300006","DOI":"10.1002\/anbr.202300006","article-title":"Ionizable lipid nanoparticles for mRNA delivery","volume":"3","author":"Tang","year":"2023","journal-title":"Adv. NanoBiomed Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e202110137","DOI":"10.1083\/jcb.202110137","article-title":"Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale","volume":"221","author":"Paramasivam","year":"2021","journal-title":"J. Cell Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e23598","DOI":"10.1002\/dvg.23598","article-title":"CRISPR-Cas9 delivery strategies and applications: Review and update","volume":"62","author":"Severi","year":"2024","journal-title":"Genesis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/17425247.2025.2466767","article-title":"GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases","volume":"22","author":"Qin","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and pharmacodynamics of GalNAc-Conjugated siRNAs","volume":"64","author":"An","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, J., Ding, Y., Chong, K., Cui, M., Cao, Z., Tang, C., Tian, Z., Hu, Y., Zhao, Y., and Jiang, S. (2024). Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. Vaccines, 12.","DOI":"10.3390\/vaccines12101148"},{"key":"ref_81","first-page":"1","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: Mechanism of action and resistance","volume":"8","author":"Pacheco","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hong, X., Cai, Z., Zhou, F., Jin, X., Wang, G., Ouyang, B., and Zhang, J. (2022). Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.932934"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2021.01.038","article-title":"Is there any need for new, long-acting nucleos (t) ide analogues for the treatment of hepatitis B infection?","volume":"74","author":"Durantel","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2300132","DOI":"10.1002\/anbr.202300132","article-title":"Advances in Nanocarriers for Delivering Therapeutic Agents Against Hepatitis B Virus","volume":"4","author":"Li","year":"2024","journal-title":"Adv. NanoBiomed Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"110107","DOI":"10.4254\/wjh.v17.i10.110107","article-title":"Hepatitis B functional cure: Current and future perspective","volume":"17","author":"Marrapu","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/HMER.S291976","article-title":"Current perspectives on Nucleos (t) ide analogue therapy for the long-term treatment of hepatitis B virus","volume":"14","author":"Broquetas","year":"2022","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s12951-024-03004-3","article-title":"Advanced siRNA delivery in combating hepatitis B virus: Mechanistic insights and recent updates","volume":"22","author":"Nguyen","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Sneller, L., Lin, C., Price, A., Kottilil, S., and Chua, J.V. (2024). RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects. Microorganisms, 12.","DOI":"10.3390\/microorganisms12030599"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41467-020-15300-1","article-title":"Imaging small molecule-induced endosomal escape of siRNA","volume":"11","author":"Hedlund","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Taverniti, V., Ligat, G., Debing, Y., Kum, D.B., Baumert, T.F., and Verrier, E.R. (2022). Capsid assembly modulators as antiviral agents against HBV: Molecular mechanisms and clinical perspectives. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051349"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e00722","DOI":"10.1128\/jvi.00722-23","article-title":"Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles","volume":"97","author":"Vanrusselt","year":"2023","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coph.2016.08.004","article-title":"Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection","volume":"30","author":"Cole","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","article-title":"Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos (t) ide analogue in patients with chronic hepatitis B infection","volume":"72","author":"Janssen","year":"2023","journal-title":"Gut"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41467-024-46706-w","article-title":"Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"15307","DOI":"10.1038\/s41598-017-15338-0","article-title":"Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP","volume":"7","author":"Donkers","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for chronic hepatitis B virus infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liver"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"116702","DOI":"10.1016\/j.biopha.2024.116702","article-title":"Targeted delivery strategies: The interactions and applications of nanoparticles in liver diseases","volume":"175","author":"Meng","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: Why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Zhao, K., Wu, L., Wu, Y., Jiang, Q., Zhu, M., Jiang, S., Zhang, C., and Lu, F. (2025). Functional cure for chronic hepatitis B: A state of immune control over cccDNA persistence. Infect. Dis. Immun.","DOI":"10.1097\/ID9.0000000000000181"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos (t) ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kayesh, M.E.H., Kohara, M., and Tsukiyama-Kohara, K. (2021). Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B: An overview. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910462"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting hepatitis B virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.antiviral.2015.10.004","article-title":"Targeting hepatitis B virus cccDNA using CRISPR\/Cas9","volume":"123","author":"Kennedy","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Boonstra, A., and Sari, G. (2025). HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication. Biomolecules, 15.","DOI":"10.3390\/biom15010062"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.cell.2025.01.033","article-title":"A nucleosome switch primes hepatitis B virus infection","volume":"188","author":"Prescott","year":"2025","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Kumar, A., Combe, E., Mougen\u00e9, L., Zoulim, F., and Testoni, B. (2024). Applications of CRISPR\/Cas as a toolbox for hepatitis B virus detection and therapeutics. Viruses, 16.","DOI":"10.3390\/v16101565"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ID9.0000000000000167","article-title":"Targeting HBV cccDNA through chromatin destabilization: A new frontier in antiviral therapy","volume":"5","author":"Cheng","year":"2025","journal-title":"Infect. Dis. Immun."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Martinez, M.G., Smekalova, E., Combe, E., Gregoire, F., Zoulim, F., and Testoni, B. (2022). Gene editing technologies to target HBV cccDNA. Viruses, 14.","DOI":"10.3390\/v14122654"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"100048","DOI":"10.1016\/j.preme.2025.100048","article-title":"CRISPR Delivery Systems for Organ-Specific Targeting: Advances and Challenges","volume":"2","author":"Du","year":"2025","journal-title":"Precis. Med. Eng."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: Challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., and Liang, Y. (2021). Nanoparticle delivery of CRISPR\/Cas9 for genome editing. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.673286"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1007\/s12274-024-6748-5","article-title":"Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing","volume":"17","author":"Guo","year":"2024","journal-title":"Nano Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.20517\/evcna.2024.19","article-title":"Endosomal escape mechanisms of extracellular vesicle-based drug carriers: Lessons for lipid nanoparticle design","volume":"5","author":"Hagedorn","year":"2024","journal-title":"Extracell. Vesicles Circ. Nucleic Acids"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/acs.langmuir.4c05176","article-title":"The Interplay of Endosomal Escape and RNA Release from Polymeric Nanoparticles","volume":"41","author":"Cheung","year":"2025","journal-title":"Langmuir"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.aohep.2024.101533","article-title":"cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B","volume":"30","author":"Naully","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: From DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"He, W., Zheng, Z., Zhao, Q., Zhang, R., and Zheng, H. (2024). Targeting HBV cccDNA levels: Key to achieving complete cure of chronic hepatitis B. Pathogens, 13.","DOI":"10.3390\/pathogens13121100"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Saeed, U., Piracha, Z.Z., Khan, M., Tariq, M.N., Gilani, S.S., Raza, M., Munusamy, R., Bose, N., Ozsahin, D.U., and \u00d6z\u015fahin, \u0130. (2025). Cracking the code of HBV persistence: Cutting-edge approaches to targeting cccDNA in chronic hepatitis B with or without pyogenic liver Abscesses. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1504736"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2018.06.093","article-title":"Cell and animal models for studying hepatitis B virus infection and drug development","volume":"156","author":"Hu","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Zhang, X., Wang, X., Wu, M., Ghildyal, R., and Yuan, Z. (2021). Animal models for the study of hepatitis B virus pathobiology and immunity: Past, present, and future. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.715450"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"114236","DOI":"10.1016\/j.addr.2022.114236","article-title":"Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics","volume":"184","author":"Vervaeke","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12951-024-02972-w","article-title":"Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: A quality-by-design approach","volume":"22","author":"Haghighi","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e70414","DOI":"10.1002\/mco2.70414","article-title":"Design strategies for novel lipid nanoparticle for mRNA vaccine and therapeutics: Current understandings and future perspectives","volume":"6","author":"Li","year":"2025","journal-title":"MedComm"},{"key":"ref_140","unstructured":"U.S. Food and Drug Administration (FDA) (2026, January 04). S12 Nonclinical Biodistribution Considerations for Gene Therapy Products: Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/167605\/download?."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.reth.2024.06.005","article-title":"Regulatory systems and requirements for clinical trials of AAV-based gene therapies\u2013Perspectives from six Asian countries or regions: Report from the 6th Asia Partnership Conference of Regenerative Medicine\u2013April 20, 2023","volume":"26","author":"Mizoguchi","year":"2024","journal-title":"Regen. Ther."},{"key":"ref_142","unstructured":"U.S. Food and Drug Administration (FDA) (2026, January 04). Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/106369\/download?."},{"key":"ref_143","unstructured":"U.S. Food and Drug Administration (FDA) (2026, January 04). Long-Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry, Available online: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Long-Term-Follow-Up-After-Admin-Human-GT-Products_Jan_2020.pdf?."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Guerrini, G., Gioria, S., Sauer, A.V., Lucchesi, S., Montagnani, F., Pastore, G., Ciabattini, A., Medaglini, D., and Calzolai, L. (2022). Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23168838"},{"key":"ref_145","first-page":"21593337251387423","article-title":"Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA\/LNP Therapies by the IQ Consortium","volume":"35","author":"Braun","year":"2025","journal-title":"Nucleic Acid Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","article-title":"Enhancing RNA-lipid nanoparticle delivery: Organ-and cell-specificity and barcoding strategies","volume":"375","author":"Wei","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Senti","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Fu, S., Zhu, X., Huang, F., and Chen, X. (2025). Anti-PEG antibodies and their biological impact on PEGylated drugs: Challenges and strategies for optimization. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17081074"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"gkaf778","DOI":"10.1093\/nar\/gkaf778","article-title":"Translational and clinical development of therapeutic siRNA and ASOs: Current industry practices, perspectives, and recommendations","volume":"53","author":"Christensen","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40259-024-00694-x","article-title":"Investigational RNA interference agents for hepatitis B","volume":"39","author":"Hui","year":"2024","journal-title":"BioDrugs"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"106321","DOI":"10.1016\/j.antiviral.2025.106321","article-title":"Update on combination therapies against HBV in clinical investigations","volume":"245","author":"Mak","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"105797","DOI":"10.4254\/wjh.v17.i4.105797","article-title":"Drug development for chronic hepatitis B functional cure: Recent progress","volume":"17","author":"Liu","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Weng, D., Zhang, C., Wei, Q., Zhang, L., Zang, X., Huang, G., Cao, Z., and Xie, Q. (2025). Combination therapies for chronic hepatitis B in the era of emerging novel drugs. Hepatol. Int.","DOI":"10.1007\/s12072-025-10888-2"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41467-025-66876-5","article-title":"An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection","volume":"17","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_156","first-page":"100408","article-title":"Nanocarrier-based immunotherapy for viral diseases","volume":"10","author":"Liu","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Ertugrul, H., Ekiz, E., Islak Mutcali, S., Tahan, V., and Daglilar, E. (2025). Chronic Hepatitis B: Current Management and Future Directions. Diseases, 13.","DOI":"10.3390\/diseases13100311"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/HEP.0000000000000430","article-title":"Pathway to global elimination of hepatitis B: HBV cure is just the first step","volume":"78","author":"Howell","year":"2023","journal-title":"Hepatology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11904-025-00763-y","article-title":"Envisioning a Multidisciplinary HBV Cure Research Agenda","volume":"22","author":"Ahmed","year":"2025","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4722047","DOI":"10.1155\/2024\/4722047","article-title":"Hepatitis B: Model Systems and Therapeutic Approaches","volume":"2024","author":"Yu","year":"2024","journal-title":"J. Immunol. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jhep.2025.03.024","article-title":"Toward functional cure of hepatitis B: Is combination therapy the key?","volume":"83","author":"Sandmann","year":"2025","journal-title":"J. Hepatol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/2\/212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:45:59Z","timestamp":1770630359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/2\/212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":161,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pharmaceutics18020212"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18020212","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]}}}